Stereotactic radiotherapy for primary lung tumors

This paper reviews the efficacy of stereotactic body radiotherapy (SBRT) in primary lung tumors, comparing it with conventional treatments. SBRT uses focused ablative doses, minimizing toxicity by limiting the area of ​​exposure. In early stages, especially in clinically inoperable patients, SBRT demonstrates superior results to conventional radiotherapy, with tumor control rates between 78% and 97%. In addition, it promotes vascular damage and induces an immune response, suggesting improved quality of life and reduced symptoms such as dyspnea and cough throughout treatment.